Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer

Jacobs, Julie; Zwaenepoel, Karen; Rolfo, Christian; Bossche, Jolien Van den; Deben, Christophe; Silence, Karen; Hermans, Christophe; Smits, Evelien; Schil, Paul Van; Lardon, Filip; Deschoolmeester, Vanessa; Pauwels, Patrick

doi:10.18632/oncotarget.3880

Cited by 47 publications

(65 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, these patients presented a lower pool of serum sCD27 compared to healthy donors (Huang et al, 2013). Notably, sCD27 did show potential as a prognostic marker in non-small cell lung cancer whereby elevated sCD27 levels correlated with reduced overall survival and progression free survival (Jacobs et al, 2015). In order to evaluate the potential use of sCD27 as a diagnostic biomarker for prognosis more research on a wide range of human malignancies is mandatory.…”

Section: Accepted Manuscriptmentioning

confidence: 95%

“…Foxp3 expression and higher CD4/CD8 ratios were found, surrounding CD70 + tumor cells in surgically resected specimens (Jacobs et al, 2015). In addition to its effect on Treg survival, another mechanism of immune escape in the tumor-microenvironment has been attributed to the CD70-CD27 pathway leading to apoptosis in lymphocytes.…”

Section: Accepted Manuscript  Signaling In the Tumor-microenvironmentmentioning

confidence: 99%

“…In B cell lymphoma, RCC and breast cancer, CD70 expression is associated with poor prognosis (Bertrand et al, 2013;Jilaveanu et al, 2012;Petrau et al, 2014). Interestingly, next to its expression on primary tumor-biopsies, stable CD70 expression is also found on patient-derived metastatic tissue in up to 100% of cases (Jacobs et al, 2015;Law et al, 2006). In literature, different methods to detect CD70 expression have been described, including real-time PCR, western blot and immunohistochemistry (IHC) .…”

Section:  Expression Patternsmentioning

confidence: 99%

See 2 more Smart Citations

CD70: An emerging target in cancer immunotherapy

Jacobs

Deschoolmeester

Zwaenepoel

et al. 2015

Pharmacology & Therapeutics

148

150

View full text Add to dashboard Cite

Over the last decades, advances in the knowledge of immunology have led to the identification of immune checkpoints, reinvigorating cancer immunotherapy. Although normally restricted to activated T and B cells, constitutive expression of CD70 in tumor cells has been described. Moreover, CD70 is implicated in tumor cell and regulatory T cell survival through interaction with its ligand, CD27. In this review, we summarize the targetable expression patterns of CD70 in a wide range of malignancies and the promising mechanism of anti-CD70 therapy in stimulating the anti-tumor immune response. In addition, we will discuss clinical data and future combination strategies.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 95%

Section: Accepted Manuscript  Signaling In the Tumor-microenvironmentmentioning

confidence: 99%

Section:  Expression Patternsmentioning

confidence: 99%

See 1 more Smart Citation

CD70: An emerging target in cancer immunotherapy

Jacobs

Deschoolmeester

Zwaenepoel

et al. 2015

Pharmacology & Therapeutics

148

150

View full text Add to dashboard Cite

show abstract

“…Next, the influence of CD70 expression on overall survival (OS) in the cohort was determined by the Kaplan-Meier analysis. To assess the association between CD70 expression and OS, we dichotomized the continuous CD70 scores into ‘positive' and ‘negative' expression (10% cut-off) [13]. Lastly, we determined the effect of TILs on OS.…”

Section: Methodsmentioning

confidence: 99%

CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck

Meulenaere¹,

Vermassen²,

Aspeslagh

et al. 2016

Pathobiology

Self Cite

View full text Add to dashboard Cite

Objective: Over the last decade, efforts have been made to get a better understanding of the tumor microenvironment and the role of the immune system in it. New insights into the CD27/CD70 signaling pathway point towards a role in tumor immunology, making CD70 an attractive target for immunotherapy. Here, we evaluate CD70 expression in squamous cell carcinoma of the head and neck (SCCHN). Methods: CD70 immunohistochemistry was retrospectively performed on 95 tumor samples. Tumoral CD70 expression was scored and correlated with clinicopathological variables and overall survival (OS). Results: CD70 expression in tumor cells was observed in 66 samples (69%) and was strongly associated with tumor differentiation grade (p < 0.001). CD70 expression was also observed in tumor-associated fibroblasts and endothelial cells. Additionally, the density of tumor-infiltrating lymphocytes correlated with OS (p = 0.042). Conclusion: This study describes the tumoral expression of CD70 in SCCHN. Results highlight the role of CD70 in tumor biology and identify CD70 as a novel therapeutic target. Further research is warranted.

show abstract

“…Of these, non-small cell lung cancer (NSCLC) represents approximately 85% [2,3] and has a dismal prognosis, with an overall 5-year survival rate of only 15% [4]. Therefore, identifying accurate predictive biomarkers is of great value in further understanding the biology of NSCLC and in developing novel therapeutic strategies.…”

Section: Introductionmentioning

confidence: 99%

Three Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting NSCLC

Tang

Cheng

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Circulating long non coding RNAs (lncRNAs) have emerged recently as major players in tumor biology and may be used for cancer diagnosis, prognosis, and as potential therapeutic targets. We explored circulating lncRNA as a predictor for the tumorigenesis of non-small-cell lung cancer (NSCLC). Methods: In this study, we applied a lncRNA microarray to screen for a potential biomarker for NSCLC, utilizing RT-PCR (ABI 7900HT). A multi-stage validation and risk score formula detection analysis was used. Results: We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls, with the merged area under the curve in the training and validation sets of 0.986 and 0.861. Furthermore, the positive predictive value and negative predictive value of the three merged factors were 0.72 and 0.87. We confirmed stable detection of the three lncRNAs by three cycles of freezing and thawing. Conclusions: RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future.

show abstract

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer

Cited by 47 publications

References 35 publications

CD70: An emerging target in cancer immunotherapy

CD70: An emerging target in cancer immunotherapy

CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck

Three Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting NSCLC

Contact Info

Product

Resources

About